Applied Clinical Trials
Clinical grant expenditures represent a major portion of the budget for later phase clinical trials.
Clinical grant expenditures represent a major portion of the budget for later phase clinical trials. Although not the ultimate reason for picking a site or region to conduct clinical trials, the relative cost of conducting a clinical trial can play an important role in the decision.
TTC provides annual current global data on the relative costs of clinical grants around the world using data pulled from the GrantPlan® database. The sponsor company and CRO subscribers to this database conduct over 76 percent of all commercial clinical trials.
Mean Costs per Subject in Phase II-III Trials
This year, the data shows that the United States remains the most expensive country for clinical grants, often by a large margin, followed by the United Kingdom. Newer geographies such as Eastern Europe, Latin America, and Asia are distinctly less expensive for clinical research.
While less expensive, these areas show more rapid increases in clinical research spending than in North America or Europe. The United States and Western Europe (excluding the United Kingdom) have been averaging 3 percent to 4 percent annual increases. In contrast, clinical grants in the new geographies are increasing at rates over 14 percent.—TTC (for more information, please contact help@ttc-llc.com).
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.